Development of a Chimpanzee Adenovirus Type 3 Ebolavirus Zaire Vaccine

EbolaVac is a European consortium composed of four leading organisations to help further advance development of a candidate vaccine against Ebola.

GlaxoSmithKline Biologicals, the University of Oxford (United Kingdom), the Bernhard Nocht Institute for Tropical Medicine (Germany) and the Hospices Cantonaux CHUV (Switzerland) have been working together since October 2014 in order to develop a Chimpanzee Adenovirus Type 3 Ebolavirus Zaire Vaccine.

About

The first Ebolavirus Zaire (EBOV) outbreak of 2014 was declared on 22nd of March in Guinea and as of 28th of September, the epidemic had spread to Liberia, Sierra Leone, Nigeria and Senegal.

Read more >>

News

As of June 2016, there have been a total of 28, 616 reported confirmed, probable, and suspected cases of Ebola Virus Disease (EVD) in Guinea, Liberia and Sierra Leone, with 11, 310 reported...

Read more >>

Consortium

The EbolaVac consortium is composed of four European partners (GSK, The University of Oxford, The Bernhard Nocht Institute for Tropical Medicine and The Hospices Cantonaux / University Hospital of...

Read more >>